Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa
NCT02465749Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2015
- Primary completion
- Jun 2025
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 1 trial of oxygen in retinitis pigmentosa (RP) (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Percentage of patients preserved 80% of the initial visual acuity at 5 years. Status: unknown.
02
Drugs
oxygen
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT02465749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465749.